IASLC and LCRF Award Team Science Grant for Lung Cancer Research | Docwire News
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
Related Articles
Phase 3 INTerpath-009 Trial of mRNA-4157 Plus Pembrolizumab for NSCLC Begins Recruitment | Docwire News
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.
Intermediate Hepatocellular Carcinoma (HCC) – Treatment Options & Strategies
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
IMbrave050 Trial Design: Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma | Docwire News
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
Subcutaneous Nivolumab for RCC: CheckMate 67T Practice-Changing Results | GU Oncology Now
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
FDA, HHS Generate Draft Guidance on Inclusion of Tissue Biopsies in Clinical Trials | Docwire News
Questions surrounding informed consent, mandatory versus optional biopsy, and safety for adults and children are addressed.
I’m a GP and bowel cancer survivor. Here’s what I eat to boost my gut health
As a busy GP and mum, Anisha relies on fresh fruit and high-protein foods like eggs to get her through the day
EC Approves Zolbetuximab Plus Chemotherapy for Advanced Gastric, GEJ Cancer | Cancer Nursing Today
The European Commission (EC) has approved zolbetuximab (Vyloytm) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment.
Unhealthy Lifestyle, The Main Trigger For Heart Disease At A Young Age
“Heart disease has been known as a degenerate disease that is synonymous with the elderly. But it is currently showing an alarming trend, because this…
Phase III CHARM Trial Evaluates Accelerated Radiation Therapy, Breast Reconstruction | Cancer Nursing Today
Using an accelerated course of radiation therapy “does not increase complications” in patients who undergo breast reconstruction after a mastectomy.
CD3-CD123 Bispecific Antibody Promising in High-Risk Myeloid Neoplasms | Blood Cancers Today
A phase 2 study highlighted the potential of CD3-CD123 bispecific T-cell engaging antibody, vibecotamab, for treatment of high-risk myeloid neoplasms.
